Henrik Andersen: How smart planning helps CGT scale further, faster

About this episode

Henrik Andersen discusses the importance of planning and strategy in scaling cell therapies.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planning, automation, and economic discipline can help scale the impact of cell therapies. Henrik draws on his experience in both biologics and cell therapy to discuss how platform thinking, target product profiles, and cost-of-goods modelling can be applied earlier in development. Together, they reflect on the pitfalls of rushing to clinic without a viable manufacturing strategy, the shift in investor expectations, and why adapting lessons from biologics could help CGT companies avoid costly detours on the path to commercial success. Connect with Henrik

People in this episode

Host: Jason C. Foster

Guest: Henrik Andersen

Topics covered

• cell therapy
• manufacturing strategy
• automation
• economic discipline
• biologics
• commercial success

Keywords

• cell therapies
• automation
• manufacturing
• biologics
• cost-of-goods
• development strategy

Mentioned in this episode

Organizations: Bristol Myers Squibb

More episodes of Ori Spotlight

• Ken Harris: Why AI and automation are CGT’s next inflection point · January 27, 2026 · 1h 3m
• Joe DePinto: Why advanced therapies need a new delivery model · January 13, 2026 · 1h 5m
• Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy · December 16, 2025 · 56 min
• John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later · December 3, 2025 · 50 min
• Warner Biddle: Building a commercial model for CAR-T in autoimmune care · September 2, 2025 · 41 min
• Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success · August 12, 2025 · 1h 0m